What To Make Of AbbVie Buying Allergan
(WorldNews Health)

AbbVie (ABBV) has been under pressure for more than a year since it made an all-time high in January 2018. At the market close on Monday, before the market reaction on Tuesday from the announcement that ABBV was buying Allergan (AGN), ABBV was trading at $78 and change per share, a P/E of about 9.4, while AGN was trading $129 per share and change, a P/E of 7.8. If bought from the closing price on Monday, AGN would be a value investment for ABBV. Unfortunately, the market always requires the acquirer to pay a premium price. What`s The Actual Deal? Based on the market close price of ABBV of $78.45 on Monday, ABBV considered AGN for about $63 billion in a cash and stock deal. AGN shareholders...